Nonalcoholic Steatohepatitis
Mostrando 1-12 de 51 artigos, teses e dissertações.
-
1. A narrative review on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis versus hepatocellular carcinoma: do you mind?
Revista da Associação Médica Brasileira. Publicado em: 2022
-
2. Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study
Abstract BACKGROUND: The long-term effects of bariatric surgery on the course of non-alcoholic fatty hepatopathy (NAFLD) are not fully understood. OBJECTIVE: To analyze the evolution of NAFLD characteristics through noninvasive markers after Roux-en-Y gastric bypass (RYGB) over a five-year period. DESIGN AND SETTING: Historical cohort study; tertiary-leve
Sao Paulo Medical Journal. Publicado em: 2022
-
3. A New Rodent Model of Non-Alcoholic Steatohepatitis and Metabolic Syndrome
Arq. Bras. Cardiol.. Publicado em: 02/12/2019
-
4. EVALUATION OF PROGRESSION OF HEPATIC FIBROSIS IN A GROUP OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANIED FOR 10 YEARS
RESUMO CONTEXTO: A doença hepática gordurosa não alcoólica vem sendo diagnosticada com frequência progressivamente maior na população geral, como consequência do aumento da prevalência da obesidade e do diabetes mellitus tipo 2, considerados seus principais fatores de risco. Caracteriza-se por acúmulo de gordura nos hepatócitos associada à infl
Arq. Gastroenterol.. Publicado em: 30/09/2019
-
5. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL
RESUMO CONTEXTO: Atualmente, o tratamento farmacológico da doença hepática gordurosa não alcoólica (DHGNA) ainda é limitado e baseia-se no tratamento de condições associadas às comorbidades. O estresse oxidativo e a resistência à insulina são os mecanismos que parecem estar mais envolvidos em sua patogênese. OBJETIVO: Avaliar a eficácia da
Arq. Gastroenterol.. Publicado em: 26/08/2019
-
6. Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
Citral is a small molecule present in various citrus species, with reported anti-hyperlipidemic and anti-inflammation effects. Here, the effect of intraperitoneal (IP) administration of citral is evaluated in a mouse model of non-alcoholic steatosis. Male NMRI mice were divided into the following groups (n = 12): normal control group (NC) receiving a normal
Braz. J. Pharm. Sci.. Publicado em: 29/11/2018
-
7. [RETRACTED ARTICLE] Characteristics of liver fibrosis with different etiologies using a fully quantitative fibrosis assessment tool
This study aimed to test the diagnostic performance of a fully quantitative fibrosis assessment tool for liver fibrosis in patients with chronic hepatitis B (CHB), primary biliary cirrhosis (PBC) and non-alcoholic steatohepatitis (NASH). A total of 117 patients with liver fibrosis were included in this study, including 50 patients with CHB, 49 patients with
Braz J Med Biol Res. Publicado em: 18/05/2017
-
8. Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?
ABSTRACT Objective The objective of this study is to evaluate the performance of mathematical models used in non-invasive diagnosis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) patients to determine when the patient needs to be referred to a hepatologist. Subjects and methods Patients referred by endocrinologists to the liver outpatient
Arch. Endocrinol. Metab.. Publicado em: 13/02/2017
-
9. Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey
Clinics. Publicado em: 2016-08
-
10. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey
OBJECTIVE: The majority of cases of hepatocellular carcinoma have been reported in individuals with cirrhosis due to chronic viral hepatitis and alcoholism, but recently, the prevalence has become increasingly related to nonalcoholic steatohepatitis around the world. The study aimed to evaluate the clinical and histophatological characteristics of hepatocel
Clinics. Publicado em: 2016-05
-
11. Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: A ten-year retrospective study
OBJECTIVE:Little is known about metabolic factors in cirrhotic patients in China. Therefore, we aimed to quantify the prevalence of both metabolic factors and non-alcoholic steatohepatitis-related liver cirrhosis in China.METHODS:The medical records of 1,582 patients diagnosed with liver cirrhosis from June 2003 to July 2013 at Daping Hospital (Chongqing, Ch
Clinics. Publicado em: 2015-08
-
12. Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) rece
Braz J Med Biol Res. Publicado em: 24/02/2015